Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp

• How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act i…
• https://x.com/RichardPAConway/status/1857823192204677592/photo/1

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK

• Rheumatoid Arthritis - Progressive Interstitial Lung Disease with Abatacept: Da…
• https://x.com/RichardPAConway/status/1857821934110572580/photo/1

Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm

• Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease. National Multi…
• https://x.com/RichardPAConway/status/1857820927368610111/photo/1

#0066 🧬Epigenetics, Gut Microbiota & RA 🔬 110 RA patients v 110 controls 🦠 Collinsella abundance a/w DNA methylation changes (PRHOXNB, TBC1D22A) in RA, correlating with disease activity. 💡❔Role of gut microbiota & epigenetic markers as RA biomarkers #ACR24 @RheumNow https://t.co/yZn0KkRpE6

• https://x.com/CaoilfhionnMD/status/1857816146025562514/photo/1

Is biologic response different in men vs women with axSpA? A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs -Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females. #Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN

• https://x.com/i/web/status/1857815900935635319
• https://x.com/AdelaCastro222/status/1857815900935635319/photo/1

Dunn et al. Are the medications recommended for RA-ILD by the ACR guidelines used in the real-world. NO! 4108 RA-ILD patients. Only 12% on one of the first line recommended therapies! @RheumNow #ACR24 Abstr#0214 https://t.co/OzW90OA1Vd https://t.co/S1MKmEDrLF

• Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheum…
• https://x.com/RichardPAConway/status/1857815896691003425/photo/1

Cool data from the JAK-POT study Have heard JAKs faster than TNF; perhaps not the case! If anything, TNFs outperformed the others in this study Trying not to over-read this, but supports my re-emerging preference for TNF #ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds

• https://x.com/EBRheum/status/1857813881176854579/photo/1
• https://x.com/EBRheum/status/1857813881176854579/photo/1

#0513 🔬 Rituximab in RA: IgG levels & infection ➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs) 🧬 IgG levels ⬇️over time (6 years/25 infusions) ⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002) #ACR24 @RheumNow

Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7

• https://x.com/JihaRheum/status/1857813377805893719/photo/1

#0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow

#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

#0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

• https://x.com/CaoilfhionnMD/status/1857806079457136834/photo/1

Which immunomodulators dampen recombinant zoster vaccine immunogenicity? In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are: - rituximab pts - 'combined therapy' strategies needed for them but reassuring for the others! #ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg

• https://x.com/drdavidliew/status/1857804958550339997/photo/1

#Frailty leads to poor outcomes and occurs earlier in RA patients. Different tools measure frailty as a phenotype vs. deficit accumulation. Discover the role of frailty in ED from #LancetRheum Ageing Series by Drs. Sarah Lieber and @KWyshamMD ! #ACR24 @RheumNow ABST#1334 https://t.co/25XQBDQMCo

• https://x.com/JihaRheum/status/1857804066287460431/photo/1

Poster#0035 🚨Postpartum RA Risk & Mucosal Immunity 👩‍🍼Elevated anti-CCP-IgG in cervicovaginal fluid of postpartum women (n=25) vs. controls. 🧪Local anti-CCP production despite negative serum ❓Childbirth-associated mucosal inflammation may drive RA onset. #ACR24 @RheumNow https://t.co/plvtyJDSY1

• https://x.com/CaoilfhionnMD/status/1857803562996117666/photo/1